Eli Lilly and Co (HAM:LLY) FFO


HAM:LLY Eli Lilly and Co HAM:LLY
98 GF Score
Price €1,039.40
GF Value €1,212.75
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Eli Lilly and Co FFO?

FFO (Funds from operations) only applies to REITs.

HAM:LLY
98GF Score
Eli Lilly and Co HAM:LLY
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Eli Lilly and Co (HAM:LLY) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of €1,039.40 is trading 14.3% below its estimated GF Value™ of €1,212.75. GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.

Key valuation signals for HAM:LLY:

  • FFO:
  • GF Value™: €1,212.75 vs. price of €1,039.40 (14.3% below fair value)
  • GF Score™: 98/100 with 6 warning signs

No single metric tells the full story. See the HAM:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
98GF Score

Get the complete analysis for HAM:LLY

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1,039.40
Price
€1,212.75
GF Value